POS0849 Long-term safety and efficacy of Upadacitinib or adalimumab in patients with rheumatoid arthritis: 5-year data from the select-compare study

Fleischmann, Roy M.;Swierkot, Jerzy;Penn, Sara;Durez, Patrick;Mysler, Eduardo;et.al.
(2023) EULAR 2023 European Congress of Rheumatology — Location: (Italy) Milano (31.May.2023)

Files

2023_EULAR_POS0849.pdf
  • Open Access
  • Adobe PDF
  • 5.78 MB
Download

Details

Authors
  • Fleischmann, Roy M.
    Author
  • Swierkot, Jerzy
    Author
  • Penn, Sara
    Author
  • Durez, PatrickUCLouvain
    Author
  • Mysler, Eduardo
    Author
Show more
Abstract
BACKGROUND: Upadacitinib (UPA) is an oral reversible Janus kinase inhibitor. In patients (pts) with RA, UPA 15mg once daily (QD) demonstrated better clinical responses at 12 weeks (wks) vs adalimumab (ADA) 40mg every other week (EOW) in the phase 3 SELECT-COMPARE study; these were maintained through 3 years (yrs) in the ongoing long-term extension (LTE), along with an acceptable safety profile.[1,2] OBJECTIVES: To assess the safety and efficacy of UPA vs ADA through 5 yrs in the SELECT-COMPARE LTE. […]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Fleischmann, R. M., Swierkot, J., Penn, S., Durez, P., Bessette, L., Bu, X., Khan, N., LI, Y., Peterfy, C., Tanaka, Y., & Mysler, E. (2023). POS0849 Long-term safety and efficacy of Upadacitinib or adalimumab in patients with rheumatoid arthritis: 5-year data from the select-compare study. Annals of the rheumatic diseases, 82(Suppl 1), 725-726. https://doi.org/10.1136/annrheumdis-2023-eular.2615 (Original work published 2023)